SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369: 16271640.
  • 2
    Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369: 16411657.
  • 3
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 15411549.
  • 4
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 10291035.
  • 5
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC I trial. Gastroenterology. 2006; 130: 323333.
  • 6
    Sandborn WJ, Hanauer SB, Enns R, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial [abstract]. Gut. 2007; 56: 12321239.
  • 7
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al; PRECISE, 2 Study Investigators. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239250.
  • 8
    Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 5265.
  • 9
    Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228238.
  • 10
    Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007; 146: 829838.
  • 11
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402413.
  • 12
    Colombel J-F, Sandborn WJ, Rutgeerts P, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009; 104: 11701179.
  • 13
    Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 14931499.
  • 14
    Colombel J-F, Schwartz DA, Sandborn WJ, et al. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut. 2009; 58: 940948.
  • 15
    Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn's Disease Activity Index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70: 439444.
  • 16
    Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106: 287296.
  • 17
    Wu EQ, Yu AP, Tang J, et al. Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn's disease. Manag Care Interface. 2008; 21: 2023.
  • 18
    Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol. 2004; 99: 19841989.
    Direct Link:
  • 19
    Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 12321239.
  • 20
    Kaplan GG, Hur C, Korzenik J, et al. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2007; 26: 15091520.
  • 21
    Loftus EV Jr, Pan P, Zurawski P, et al. Patterns and predictors of dosage increase in patients treated with adalimumab for Crohn's disease in the United States. J Crohns Colitis. 2009; 3: S7.
  • 22
    HUMIRA [summary of product characteristics]. Kent, UK: Abbott Laboratories. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/humira/emea-combined-h481en.pdf Accessed February 15, 2010.
  • 23
    HUMIRA [prescribing information]. North Chicago, IL: Abbott Laboratories; 2010.
  • 24
    Regueiro M, Siemanowski B, Kip KE, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007; 13: 10931099.
  • 25
    Wu EQ, Mulani PM, Yu A, et al. Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective. Value Health. 2008; 11: 820829.
  • 26
    Sandborn WJ, Hanauer SB, Rutgeerts PJ, et al. Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECiSE 4 results. Gastroenterology. 2007; 132( 4 Suppl 1): A505.
  • 27
    Sandborn WJ, D'Haens G, Vermeire S, et al. Regain of response and remission by dose adjustment in patients with Crohn's disease who responded to certolizumab pegol: results from the WELCOME study. Am J Gastroenterol. 2009; 104( Suppl 3): S450S451.
  • 28
    Sandborn WJ, Vermeire S, D'Haens G, et al. WELCOME: a randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab. Gastroenterology. 2009; 136( 5 Suppl 1): A-27.